| 1 | study | 296,526 |
| 2 | pilot-study | 12 |
| 3 | studys | 6 |
| 4 | meta-analysis.in | 5 |
| 5 | life-study | 4 |
| 6 | ox-foot-model | 3 |
| 7 | sudy | 3 |
| 8 | addition-study | 2 |
| 9 | bamse | 2 |
| 10 | burden-of-illness-study | 2 |
| 11 | dat'aids | 2 |
| 12 | effect.there | 2 |
| 13 | hyperandrogenization | 2 |
| 14 | nano-immunoassay | 2 |
| 15 | opticath | 2 |
| 16 | pfb-ap | 2 |
| 17 | pharmacop-trial | 2 |
| 18 | qids-sr. | 2 |
| 19 | trials.for | 2 |
| 20 | 110-year-old | 1 |
| 21 | 40302 | 1 |
| 22 | 57.8° | 1 |
| 23 | acupoint-selection | 1 |
| 24 | african-origin | 1 |
| 25 | and-treatment | 1 |
| 26 | aristides | 1 |
| 27 | biotcm-se | 1 |
| 28 | counter-arguments | 1 |
| 29 | dutch-were | 1 |
| 30 | enzymopathy | 1 |
| 31 | eurostar-study | 1 |
| 32 | fachklinikum | 1 |
| 33 | first-cut | 1 |
| 34 | flavivirus-exposed | 1 |
| 35 | haploblock | 1 |
| 36 | iferythema | 1 |
| 37 | low-exposed | 1 |
| 38 | one-drug | 1 |
| 39 | overreview | 1 |
| 40 | paquid | 1 |
| 41 | period.migrants | 1 |
| 42 | phosphosequence | 1 |
| 43 | post-hocanalysis | 1 |
| 44 | pre-2ndplyex | 1 |
| 45 | review.important | 1 |
| 46 | strip-project | 1 |
| 47 | study.after | 1 |
| 48 | study.all | 1 |
| 49 | study.immunohistochemistry | 1 |
| 50 | study.recessions | 1 |
| 51 | study.urine | 1 |
| 52 | target-dose | 1 |
| 53 | taxus-stent | 1 |
| 54 | thinking—which | 1 |
| 55 | trials-supraspinatus | 1 |
| 56 | unconven-tional | 1 |
| 57 | update.there | 1 |
| 1 | 110-year-old | 1 |
| 2 | 40302 | 1 |
| 3 | 57.8° | 1 |
| 4 | acupoint-selection | 1 |
| 5 | addition-study | 2 |
| 6 | african-origin | 1 |
| 7 | and-treatment | 1 |
| 8 | aristides | 1 |
| 9 | bamse | 2 |
| 10 | biotcm-se | 1 |
| 11 | burden-of-illness-study | 2 |
| 12 | counter-arguments | 1 |
| 13 | dat'aids | 2 |
| 14 | dutch-were | 1 |
| 15 | effect.there | 2 |
| 16 | enzymopathy | 1 |
| 17 | eurostar-study | 1 |
| 18 | fachklinikum | 1 |
| 19 | first-cut | 1 |
| 20 | flavivirus-exposed | 1 |
| 21 | haploblock | 1 |
| 22 | hyperandrogenization | 2 |
| 23 | iferythema | 1 |
| 24 | life-study | 4 |
| 25 | low-exposed | 1 |
| 26 | meta-analysis.in | 5 |
| 27 | nano-immunoassay | 2 |
| 28 | one-drug | 1 |
| 29 | opticath | 2 |
| 30 | overreview | 1 |
| 31 | ox-foot-model | 3 |
| 32 | paquid | 1 |
| 33 | period.migrants | 1 |
| 34 | pfb-ap | 2 |
| 35 | pharmacop-trial | 2 |
| 36 | phosphosequence | 1 |
| 37 | pilot-study | 12 |
| 38 | post-hocanalysis | 1 |
| 39 | pre-2ndplyex | 1 |
| 40 | qids-sr. | 2 |
| 41 | review.important | 1 |
| 42 | strip-project | 1 |
| 43 | study | 296,526 |
| 44 | study.after | 1 |
| 45 | study.all | 1 |
| 46 | study.immunohistochemistry | 1 |
| 47 | study.recessions | 1 |
| 48 | study.urine | 1 |
| 49 | studys | 6 |
| 50 | sudy | 3 |
| 51 | target-dose | 1 |
| 52 | taxus-stent | 1 |
| 53 | thinking—which | 1 |
| 54 | trials-supraspinatus | 1 |
| 55 | trials.for | 2 |
| 56 | unconven-tional | 1 |
| 57 | update.there | 1 |
| 1 | qids-sr. | 2 |
| 2 | 40302 | 1 |
| 3 | iferythema | 1 |
| 4 | flavivirus-exposed | 1 |
| 5 | low-exposed | 1 |
| 6 | paquid | 1 |
| 7 | 110-year-old | 1 |
| 8 | phosphosequence | 1 |
| 9 | study.urine | 1 |
| 10 | update.there | 1 |
| 11 | effect.there | 2 |
| 12 | dutch-were | 1 |
| 13 | biotcm-se | 1 |
| 14 | bamse | 2 |
| 15 | target-dose | 1 |
| 16 | one-drug | 1 |
| 17 | thinking—which | 1 |
| 18 | opticath | 2 |
| 19 | haploblock | 1 |
| 20 | pharmacop-trial | 2 |
| 21 | unconven-tional | 1 |
| 22 | ox-foot-model | 3 |
| 23 | study.all | 1 |
| 24 | fachklinikum | 1 |
| 25 | meta-analysis.in | 5 |
| 26 | african-origin | 1 |
| 27 | hyperandrogenization | 2 |
| 28 | acupoint-selection | 1 |
| 29 | pfb-ap | 2 |
| 30 | study.after | 1 |
| 31 | trials.for | 2 |
| 32 | dat'aids | 2 |
| 33 | aristides | 1 |
| 34 | post-hocanalysis | 1 |
| 35 | study.recessions | 1 |
| 36 | period.migrants | 1 |
| 37 | counter-arguments | 1 |
| 38 | trials-supraspinatus | 1 |
| 39 | studys | 6 |
| 40 | strip-project | 1 |
| 41 | review.important | 1 |
| 42 | and-treatment | 1 |
| 43 | taxus-stent | 1 |
| 44 | first-cut | 1 |
| 45 | overreview | 1 |
| 46 | pre-2ndplyex | 1 |
| 47 | nano-immunoassay | 2 |
| 48 | sudy | 3 |
| 49 | study | 296,526 |
| 50 | life-study | 4 |
| 51 | addition-study | 2 |
| 52 | eurostar-study | 1 |
| 53 | burden-of-illness-study | 2 |
| 54 | pilot-study | 12 |
| 55 | enzymopathy | 1 |
| 56 | study.immunohistochemistry | 1 |
| 57 | 57.8° | 1 |